株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

脳内出血:パイプラインレビュー

Intracerebral Hemorrhage - Pipeline Review, H2 2014

発行 Global Markets Direct 商品コード 319633
出版日 ページ情報 英文 38 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
脳内出血:パイプラインレビュー Intracerebral Hemorrhage - Pipeline Review, H2 2014
出版日: 2014年11月18日 ページ情報: 英文 38 Pages
概要

脳内出血(ICH)は、血液が突然脳組織に流れ込んだ時に起こり、脳にダメージを与え、脳卒中に似た症状が現れます。症候にはひどい頭痛が突然起こったり、嚥下困難、片眼あるいは両眼の視覚障害、バランスと運動感覚の喪失、眩暈、吐き気、精神錯乱等が挙げられます。 リスク要因としては頭部の怪我や身体的外傷、腫瘍の出血、血友病や鎌状赤血球貧血などといった、出血性疾患が挙げられます。

当レポートでは、脳内出血の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

脳内出血 概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;比較分析

企業で開発中の治療薬

パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

企業で開発中の製品

治療薬開発に従事している企業

  • ActiveSite Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd.
  • MediPost Co., Ltd.
  • Pfizer Inc.

治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • alteplase
  • ASP-440
  • PF-05230907
  • Pneumostem
  • Stem Cell Therapy for Cerebral Hemorrhage

最近のパイプライン動向

休止中のプロジェクト

開発が中止された製品

付録

図表

目次
Product Code: GMDHC5731IDB

Summary

Global Markets Direct's, 'Intracerebral Hemorrhage - Pipeline Review, H2 2014', provides an overview of the Intracerebral Hemorrhage's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Intracerebral Hemorrhage, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Intracerebral Hemorrhage and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Intracerebral Hemorrhage
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Intracerebral Hemorrhage and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Intracerebral Hemorrhage products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Intracerebral Hemorrhage pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Intracerebral Hemorrhage
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Intracerebral Hemorrhage pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Intracerebral Hemorrhage Overview
  • Therapeutics Development
    • Pipeline Products for Intracerebral Hemorrhage - Overview
    • Pipeline Products for Intracerebral Hemorrhage - Comparative Analysis
  • Intracerebral Hemorrhage - Therapeutics under Development by Companies
  • Intracerebral Hemorrhage - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Intracerebral Hemorrhage - Products under Development by Companies
  • Intracerebral Hemorrhage - Companies Involved in Therapeutics Development
    • ActiveSite Pharmaceuticals, Inc.
    • F. Hoffmann-La Roche Ltd.
    • MediPost Co., Ltd.
    • Pfizer Inc.
  • Intracerebral Hemorrhage - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • alteplase - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ASP-440 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PF-05230907 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Pneumostem - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Stem Cell Therapy for Cerebral Hemorrhage - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Intracerebral Hemorrhage - Recent Pipeline Updates
  • Intracerebral Hemorrhage - Dormant Projects
  • Intracerebral Hemorrhage - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Intracerebral Hemorrhage, H2 2014
  • Number of Products under Development for Intracerebral Hemorrhage - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Comparative Analysis by Late Stage Development, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Development, H2 2014
  • Products under Development by Companies, H2 2014
  • Intracerebral Hemorrhage - Pipeline by ActiveSite Pharmaceuticals, Inc., H2 2014
  • Intracerebral Hemorrhage - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014
  • Intracerebral Hemorrhage - Pipeline by MediPost Co., Ltd., H2 2014
  • Intracerebral Hemorrhage - Pipeline by Pfizer Inc., H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Stage and Target, H2 2014
  • Number of Products by Stage and Mechanism of Action, H2 2014
  • Number of Products by Stage and Route of Administration, H2 2014
  • Number of Products by Stage and Molecule Type, H2 2014
  • Intracerebral Hemorrhage Therapeutics - Recent Pipeline Updates, H2 2014
  • Intracerebral Hemorrhage - Dormant Projects, H2 2014
  • Intracerebral Hemorrhage - Discontinued Products, H2 2014

List of Figures

  • Number of Products under Development for Intracerebral Hemorrhage, H2 2014
  • Number of Products under Development for Intracerebral Hemorrhage - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Top 10 Targets, H2 2014
  • Number of Products by Stage and Top 10 Targets, H2 2014
  • Number of Products by Top 10 Mechanism of Actions, H2 2014
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014
  • Number of Products by Top 10 Routes of Administration, H2 2014
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2014
  • Number of Products by Top 10 Molecule Types, H2 2014
  • Number of Products by Stage and Top 10 Molecule Types, H2 2014
Back to Top